The role of IL-1B in breast cancer bone metastasis
- PMID: 29760166
- PMCID: PMC5987176
- DOI: 10.1530/ERC-17-0309
The role of IL-1B in breast cancer bone metastasis
Abstract
Approximately 75% of patients with late-stage breast cancer will develop bone metastasis. This condition is currently considered incurable and patients' life expectancy is limited to 2-3 years following diagnosis of bone involvement. Interleukin (IL)-1B is a pro-inflammatory cytokine whose expression in primary tumours has been identified as a potential biomarker for predicting breast cancer patients at increased risk for developing bone metastasis. In this review, we discuss how IL-1B from both the tumour cells and the tumour microenvironment influence growth of primary breast tumours, dissemination into the bone metastatic niche and proliferation into overt metastases. Recent evidence indicates that targeting IL-1B signalling may provide promising new treatments that can hold tumour cells in a dormant state within bone thus preventing formation of overt bone metastases.
Keywords: IL-1B; bone metastasis; breast cancer.
© 2018 The authors.
Figures



Similar articles
-
IL-1β in breast cancer bone metastasis.Expert Rev Mol Med. 2022 Mar 1;24:e11. doi: 10.1017/erm.2022.4. Expert Rev Mol Med. 2022. PMID: 35227338 Review.
-
IL-1 drives breast cancer growth and bone metastasis in vivo.Oncotarget. 2016 Nov 15;7(46):75571-75584. doi: 10.18632/oncotarget.12289. Oncotarget. 2016. PMID: 27765923 Free PMC article.
-
IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer.NPJ Breast Cancer. 2021 Jul 21;7(1):95. doi: 10.1038/s41523-021-00305-w. NPJ Breast Cancer. 2021. PMID: 34290237 Free PMC article.
-
Development of clinically relevant in vivo metastasis models using human bone discs and breast cancer patient-derived xenografts.Breast Cancer Res. 2019 Nov 29;21(1):130. doi: 10.1186/s13058-019-1220-2. Breast Cancer Res. 2019. PMID: 31783893 Free PMC article.
-
Interleukins as Mediators of the Tumor Cell-Bone Cell Crosstalk during the Initiation of Breast Cancer Bone Metastasis.Int J Mol Sci. 2021 Mar 12;22(6):2898. doi: 10.3390/ijms22062898. Int J Mol Sci. 2021. PMID: 33809315 Free PMC article. Review.
Cited by
-
Edodes Cultured Extract Regulates Immune Stress During Puberty and Modulates MicroRNAs Involved in Mammary Gland Development and Breast Cancer Suppression.Cancer Med. 2024 Oct;13(19):e70277. doi: 10.1002/cam4.70277. Cancer Med. 2024. PMID: 39382253 Free PMC article.
-
Tumor associated macrophages in breast cancer progression: implications and clinical relevance.Front Immunol. 2024 Jul 9;15:1441820. doi: 10.3389/fimmu.2024.1441820. eCollection 2024. Front Immunol. 2024. PMID: 39044824 Free PMC article. Review.
-
PD-L1 Blockade by Atezolizumab Downregulates Signaling Pathways Associated with Tumor Growth, Metastasis, and Hypoxia in Human Triple Negative Breast Cancer.Cancers (Basel). 2019 Jul 25;11(8):1050. doi: 10.3390/cancers11081050. Cancers (Basel). 2019. PMID: 31349612 Free PMC article.
-
Evaluating the Role of IL-1β in Transmigration of Triple Negative Breast Cancer Cells Across the Brain Endothelium.Cell Mol Bioeng. 2021 Oct 26;15(1):99-114. doi: 10.1007/s12195-021-00710-y. eCollection 2022 Feb. Cell Mol Bioeng. 2021. PMID: 35096187 Free PMC article.
-
Treating pathological metastatic fractures of the humerus by compound osteosynthesis: a retrospective cohort study.JSES Int. 2024 Jan 11;8(3):446-450. doi: 10.1016/j.jseint.2023.12.002. eCollection 2024 May. JSES Int. 2024. PMID: 38707561 Free PMC article.
References
-
- Baroja-Mazo A, Martin-Sanchez F, Gomez AI, Martinez CM, Amores-Iniesta J, Compan V, Barbera-Cremades M, Yague J, Ruiz-Ortiz E, Anton J, et al 2014. The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nature Immunology 15 738–748. (10.1038/ni.2919) - DOI - PubMed
-
- Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. 2007. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Research 67 10019–10026. (10.1158/0008-5472.CAN-07-2354) - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical